AstraZeneca has selected Charles River Laboratories International as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics). The three-year agreement extends into 2015. AZ began the process of transferring programs to Charles River earlier this year. This process is expected to be completed by early 2013. Terms were not disclosed, but CRL reported that incremental sales under this agreement are expected to contribute...